Lorqess

Uses

Lorqess is a serotonin 2C receptor agonist used in conjunction with physical activity and calorie restriction for weight loss in obese patients with a body mass index (BMI) of 30 and above, and in overweight patients with weight-related comorbidities.

For the treatment of obesity, as an adjunct to a reduced-calorie diet and increased physical activity.

Lorqess is also used to associated treatment for these conditions: BMI >30 kg/m2

How Lorqess works

Although the exact mechanism is unknown, it is believed to involve the selective activation of 5-HT2C receptors in the anorexigenic pro-opiomelanocortin neurons in the arcuate nucleus of the hypothalamus. This results in decreased food intake and satiety by promoting the release of alpha-melanocortin stimulating hormone, which acts on melanocortin-4 receptors.

Toxicity

Most common adverse reactions include hypoglycemia (diabetic patients), headache, back pain,fatigue, decrease in lymphocytes,upper respiratory tract infection, and nasopharyngitis. Moreover, the safety and efficacy of coadministration with other weight loss products has not been established, and cardiovascular effects on mortality and morbidity have not been established.

Food Interaction

• Take with or without food.

[Minor] Food does not appear to significantly affect the absorption and oral bioavailability of lurasidone.

In twelve adult volunteers (6 men and 6 women), administration of a single 10 mg oral dose of lorcaserin following a high-fat (approximately 50% of total caloric content of the meal) and high-calorie (approximately 800 to 1000 calories) meal resulted in less than 10% increases in lorcaserin peak plasma concentration (Cmax) and systemic exposure (AUC) compared to administration in the fasted state.

The time to reach peak concentration (Tmax) was delayed by approximately 1 hour in the fed state.

Lorqess may be administered with or without food.

Lorqess Drug Interaction

Major: duloxetineModerate: amphetamine / dextroamphetamine, lurasidone, semaglutide, dulaglutideUnknown: aspirin, aspirin, lorazepam, buprenorphine, ubiquinone, azelastine / fluticasone nasal, omega-3 polyunsaturated fatty acids, sulfacetamide sodium topical, metronidazole topical, acetaminophen, hydroxychloroquine, omeprazole, budesonide / formoterol, levothyroxine, cholecalciferol

Lorqess Disease Interaction

Major: valvulopathyModerate: bradycardia, breast cancer, depression, hematological abnormalities, liver disease, priapism, pulmonary hypertension, renal dysfunction, diabetics

Volume of Distribution

The volume of distribution was not determined, but lorcaserin distributes to the central nervous system and cerebrospinal fluid.

Elimination Route

Lorqess has a peak plasma concentration of about 1.5 - 2 hours, but the bioavailability was not determined.

Half Life

The plasma half life is approximately 11 hours.

Clearance

The clearance value was not determined.

Elimination Route

Lorqess is eliminated by hepatic metabolism, and the metabolites are eliminated mostly in the urine (92.3%) and some through feces (2.2%).

Innovators Monograph

You find simplified version here Lorqess